MBS item

73313
=====

Quantitative molecular assay for measurable residual disease in acute lymphoblastic leukaemia using bone marrow or peripheral blood, once per patient per episode or relapse, ordered by a haematologist or oncologist.

Category 6 · Pathology services[Group P7](/groups/P7)

Schedule fee$3,000.00

100% benefitGP, out of hospital—

85% benefitOut of hospital$2,895.50

75% benefitIn hospital$2,250.00

The schedule fee for MBS item 73313 is $3,000.00. Medicare pays $2,895.50 (85%) out of hospital, or $2,250.00 (75%) for a privately admitted patient in hospital. Fee effective 1 July 2024.

Gap for what you charge
-----------------------

Your fee$

Out of hospitalIn hospital (private)

Medicare pays$2,895.50

Patient gap$104.50

Bulk billing means accepting $2,895.50 as full payment, with no gap and no extra charges. [Add incentives](/bulk-billing?item=73313)

Item descriptor
---------------

Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse

[Explanatory notes and rules on MBS Online ↗](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=73313)

Health fund and DVA rates
-------------------------

Total fee each scheme recognises for this item in hospital.

StateNSWVICQLDSAWATASACTNT

Guides
------

- [How Medicare benefits work: schedule fees, 75%, 85% and 100%](/guides/how-medicare-benefits-work)
- [Medicare safety nets explained: original and extended (EMSN) thresholds for 2026](/guides/medicare-safety-nets)
- [In-hospital billing: the 75% benefit, the 25% fund benefit, and no-gap and known-gap schemes](/guides/in-hospital-billing-and-gap-cover)
- [Bulk billing incentives and BBPIP explained: 2026 amounts by MM area](/guides/bulk-billing-incentives)
- [The MBS multiple operation rule and surgical assistant fees](/guides/multiple-operation-rule)
- [Assignment of benefit for bulk billing: the changes from 1 July 2026](/guides/assignment-of-benefit-2026)
- [MBS telehealth rules: the eligible telehealth practitioner and phone items](/guides/mbs-telehealth-rules)
- [GP chronic condition management plans: items 965 and 967 explained](/guides/chronic-condition-management-plans)
- [Medicare billing compliance: claim time limits, records and the 80/20 rule](/guides/medicare-billing-compliance)

Data source: [Australian Government Medicare Benefits Schedule](https://www.mbsonline.gov.au/) · Record updated 1 September 2026. Health fund rates come from each fund's published schedule. Verify item descriptors, rules and fees on [MBS Online](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=73313) before billing. This is a reference tool, not billing or financial advice.